• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Automated CRISPR/Cas9-based genome editing of human pluripotent stem cells using the StemCellFactory
 
  • Details
  • Full
Options
September 20, 2024
Journal Article
Title

Automated CRISPR/Cas9-based genome editing of human pluripotent stem cells using the StemCellFactory

Abstract
CRISPR/Cas9 genome editing is a rapidly advancing technology that has the potential to accelerate research and development in a variety of fields. However, manual genome editing processes suffer from limitations in scalability, efficiency, and standardization. The implementation of automated systems for genome editing addresses these challenges, allowing researchers to cover the increasing need and perform large-scale studies for disease modeling, drug development, and personalized medicine. In this study, we developed an automated CRISPR/Cas9-based genome editing process on the StemCellFactory platform. We implemented a 4D-Nucleofector with a 96-well shuttle device into the StemCellFactory, optimized several parameters for single cell culturing and established an automated workflow for CRISPR/Cas9-based genome editing. When validated with a variety of genetic backgrounds and target genes, the automated workflow showed genome editing efficiencies similar to manual methods, with indel rates of up to 98%. Monoclonal colony growth was achieved and monitored using the StemCellFactory-integrated CellCelector, which allowed the exclusion of colonies derived from multiple cells or growing too close to neighbouring colonies. In summary, we demonstrate the successful establishment of an automated CRISPR/Cas9-based genome editing process on the StemCellFactory platform. The development of such a standardized and scalable automated CRISPR/Cas9 system represents an exciting new tool in genome editing, enhancing our ability to address a wide range of scientific questions in disease modeling, drug development and personalized medicine.
Author(s)
Nießing, Bastian  
Fraunhofer-Institut für Produktionstechnologie IPT  
Breitkreuz, Yannik
Elanzew, Andreas
University of Bonn
de Toledo, Marcelo A.S.
RWTH Aachen University  
Vajs, Peter
Fraunhofer-Institut für Produktionstechnologie IPT  
Nolden, Marina
Fraunhofer-Institut für Produktionstechnologie IPT  
Erkens, Frederik  
Fraunhofer-Institut für Produktionstechnologie IPT  
Wanek, Paul
RWTH Aachen University  
Au Yeung, Si Wah Christina
University of Bonn
Haupt, Simone
König, Niels  
Fraunhofer-Institut für Produktionstechnologie IPT  
Peitz, Michael
Michael
Schmitt, Robert H.  
Fraunhofer-Institut für Produktionstechnologie IPT  
Zenke, Martin
RWTH Aachen University  
Brüstle, Oliver
Journal
Frontiers in Bioengineering and Biotechnology  
Project(s)
Standardisierte und integrierte Verfahren zur personalisierten stammzellbasierten Wirkstoffprädiktion mittels reprogrammierter Blutzellen  
MAST
Funder
European Commission  
Open Access
DOI
10.24406/publica-3708
10.3389/fbioe.2024.1459273
File(s)
Full text.pdf (2.52 MB)
Rights
CC BY 4.0: Creative Commons Attribution
Language
English
Fraunhofer-Institut für Produktionstechnologie IPT  
Keyword(s)
  • iPS

  • Genome editing

  • CRISPR/Cas9

  • Automation

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024